Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment
Keywords:
pemphigus, pemphigoid, autoimmune, bullous, disorderAbstract
Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders characterized by the production of autoantibodies against adhesion molecules of the skin. The 2 major groups of diseases are “pemphigus diseases” and “autoimmune bullous diseases of the pemphigoid type.” Pemphigus diseases are a group of autoimmune blistering diseases of the skin and mucous membranes characterized by intraepithelial cleft and acantholysis. The main subtypes of pemphigus include pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. Diagnosis is based on clinical manifestations and confirmed with histological, immunofluorescence, and serological testing. Recently multivariant enzyme‐linked immunosorbent assay systems have been developed as practical screening tools for patients with suspected autoimmune bullous dermatoses. The current first-line treatment of pemphigus is based on systemic corticosteroids that are often combined with immunosuppressive adjuvants, such as azathioprine, mycophenolate mofetil, and the anti-CD20 monoclonal antibody rituximab, usually at initiation of treatment. Rituximab efficacy is higher when it is administered early in the course of the disease. Therefore, it should be used as first-line treatment to improve efficacy and reduce cumulative doses of corticosteroids and their side effects. Treatment of bullous pemphigoid is based on disease extension. Localized and mild forms can be treated with superpotent topical corticosteroids or with nonimmunosuppressive agents. In patients with generalized disease or whose disease is resistant to the treatments described above, systemic corticosteroids are preferred and effective. Adjuvant immunosuppressants are often combined with steroids for their steroid-sparing effect.
References
. https://doi.org/10.1111/jdv.15770
Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol. 1999;140(2):351-357. https://doi.org/10.1046/j.1365-2133.1999.02752.x
Jamora MJ, Jiao D, Bystryn JC. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J Am Acad Dermatol. 2003;48(6):976-977. https://doi.org/10.1067/mjd.2003.438
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445-455. https://doi.org/10.1016/j.autrev.2017.03.010
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-585.e1. https://doi.org/10.1016/j.jaad.2018.02.021
Almugairen N, Hospital V, Bedane C, et al. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69(4):583-588. https://doi.org/10.1016/j.jaad.2013.05.016
Mentink LF, Mackenzie MW, Tóth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142(5):570-576. https://doi.org/10.1001/archderm.142.5.570
Sharma VK, Gupta V, Bhari N, Singh V. Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up. Int J Dermatol. 2020;59(1):76-81. https://doi.org/10.1111/ijd.14546
De D, Bishnoi A, Handa S, Mahapatra T, Mahajan R. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: a retrospective single-center review of up to 68 months follow-up. Indian J Dermatol Venereol Leprol. 2020;86(1):39-44. https://doi.org/10.4103/ijdvl.IJDVL_848_17
Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928-932. https://doi.org/10.2340/00015555-2116
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. https://doi.org/10.1016/S0140-6736(17)30070-3
Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111-1119. https://doi.org/10.1111/bjd.18482
Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32(5):e13016. https://doi.org/10.1111/dth.13016
Albers LN, Liu Y, Bo N, Swerlick RA, Feldman RJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074-1082. https://doi.org/10.1016/j.jaad.2017.07.012
Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79(1):97-103. https://doi.org/10.1016/j.jaad.2018.01.029
Sharma VK, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol. 2016;82(4):389-394. https://doi.org/10.4103/0378-6323.174379
de Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. Br J Dermatol. 2015;172(5):1420-1423. https://doi.org/10.1111/bjd.13586
Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13(8):833-844. https://doi.org/10.1111/ddg.12606
Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid: a summarised Cochrane review. Clin Exp Dermatol. 2011;36(4):449-450. https://doi.org/10.1111/j.1365-2230.2011.04104.x
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. https://doi.org/10.1056/NEJMoa011592
Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(1):1681-1687. https://doi.org/10.1038/jid.2008.412
Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630-1638. https://doi.org/10.1016/S0140-6736(17)30560-3
Yamagami J. Recent advances in the understanding and treatment of pemphigus and pemphigoid. F1000Res. 2018;7:F1000 Faculty Rev-1360. Published 2018 Aug 30. https://doi.org/10.12688/f1000research.14474.1
Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299-1305. https://doi.org/10.1111/bjd.15649
Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209-216. https://doi.org/10.1007/s40257-018-0401-6
Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78(15):1527-1548. https://doi.org/10.1007/s40265-018-0976-5
Seyed Jafari SM, Gadaldi K, Feldmeyer L, Yawalkar N, Borradori L, Schlapbach C. Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid. Front Immunol. 2019;10:1919. https://doi.org/10.3389/fimmu.2019.01919
Bilgic A, Murrell DF. What is novel in the clinical management of pemphigus. Expert Rev Clin Pharmacol. 2019;12(10):973-980. https://doi.org/10.1080/17512433.2019.1670059
Langenhan J, Dworschak J, Saschenbrecker S, et al. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol. 2014;23(4):253-259. https://doi.org/10.1111/exd.12355
Hofrichter M, Dworschak J, Emtenani S, et al. Immunoadsorption of desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. Front Immunol. 2018;9:1935. https://doi.org/10.3389/fimmu.2018.01935
Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179-184. https://doi.org/10.1126/science.aaf6756
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418. https://doi.org/10.3389/fimmu.2019.01418
Wannick M, Assmann JC, Vielhauer JF, et al. The immunometabolomic interface receptor hydroxycarboxylic acid receptor 2 mediates the therapeutic effects of dimethyl fumarate in autoantibody-induced skin inflammation. Front Immunol. 2018;9:1890. https://doi.org/10.3389/fimmu.2018.01890
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
